FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc. (NASDAQ: VERV) in a deal valued at up to $1.3 billion, according to the Financial Times. This move underscores Eli Lilly’s aggressive expansion into genetic medicine as it seeks to boost its pipeline of experimental drugs.
Verve Therapeutics’ stock skyrocketed nearly 73% in after-hours trading, reaching $10.76, following the news. The proposed deal would include a $1 billion upfront payment and an additional $300 million tied to performance-based milestones. The acquisition price values Verve at approximately double its market capitalization of just over $500 million as of Monday's close.
The Boston-based Verve specializes in in vivo gene editing treatments aimed at cardiovascular disease. Eli Lilly’s interest lies in leveraging Verve’s proprietary CRISPR-based technology to diversify and enhance its R&D capabilities.
This potential acquisition adds to Eli Lilly’s recent M&A streak. Earlier in 2025, the pharmaceutical giant acquired Scorpion Therapeutics for $2.5 billion and SiteOne Therapeutics for $1 billion, signaling a clear strategy to invest in innovative biotech platforms.
Despite broader industry challenges, Eli Lilly continues to outperform competitors, driven by strong sales of its diabetes and weight-loss drugs Mounjaro and Zepbound. By acquiring Verve, Lilly aims to strengthen its long-term competitiveness in the fast-evolving field of gene therapies.
Investors are watching closely as the deal, if finalized, could mark a major turning point for both companies and the broader gene editing space. Eli Lilly’s push into advanced therapeutics reaffirms its leadership in shaping the future of precision medicine and biopharmaceutical innovation.
